Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A
nationwide multi-centred randomised controlled trial (RCT) investigating the use of GLM dose
adjustment in ulcerative colitis (UC). The primary objective is to ascertain if dose
adjustment of GLM based on GLM drug levels and FCP levels results in higher response and
remission rates than standard SmPC dosing.